Visualization of Human T Lymphocyte-Mediated Eradication of Cancer Cells in Vivo
Xingkang He,Xin Yin,Jing Wu,Stina L. Wickstrom,Yanhong Duo,Qiqiao Du,Shuhang Qin,Shuzhong Yao,Xu Jing,Kayoko Hosaka,Jieyu Wu,Lasse D. Jensen,Andreas Lundqvist,Alexander Salter,Lars Brautigam,Wei Tao,Yuguo Chen,Rolf Kiessling,Yihai Cao
DOI: https://doi.org/10.1073/pnas.2009092117
IF: 11.1
2020-01-01
Proceedings of the National Academy of Sciences
Abstract:Lymphocyte-based immunotherapy has emerged as a break-through in cancer therapy for both hematologic and solid malignancies. In a subpopulation of cancer patients, this powerful therapeutic modality converts malignancy to clinically manageable disease. However, the T cell- and chimeric antigen receptor T (CAR-T) cell-mediated antimetastatic activity, especially their impacts on microscopic metastatic lesions, has not yet been investigated. Here we report a living zebrafish model that allows us to visualize the metastatic cancer cell killing effect by tumor- infiltrating lymphocytes (TILs) and CAR-T cells in vivo at the single-cell level. In a freshly isolated primary human melanoma, specific TILs effectively eliminated metastatic cancer cells in the living body. This potent metastasis-eradicating effect was validated using a human lymphoma model with CAR-T cells. Furthermore, cancer-associated fibroblasts protected metastatic cancer cells from T cell-mediated killing. Our data provide an in vivo platform to validate antimetastatic effects by human T cell-mediated immunotherapy. This unique technology may serve as a precision medicine platform for assessing anticancer effects of cellular immunotherapy in vivo before administration to human cancer patients.